JP2016524609A - メントール及び／又はイシリンを用いるうつ病の処置又は予防 - Google Patents

メントール及び／又はイシリンを用いるうつ病の処置又は予防 Download PDF

Info

Publication number
JP2016524609A
JP2016524609A JP2016514430A JP2016514430A JP2016524609A JP 2016524609 A JP2016524609 A JP 2016524609A JP 2016514430 A JP2016514430 A JP 2016514430A JP 2016514430 A JP2016514430 A JP 2016514430A JP 2016524609 A JP2016524609 A JP 2016524609A
Authority
JP
Japan
Prior art keywords
depression
composition
menthol
icilin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016514430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016524609A5 (enExample
Inventor
スサナ カマチョ，
スサナ カマチョ，
ゴンザレス， ステファニー ミヒリク
ゴンザレス， ステファニー ミヒリク
クトレ， ヨハネス ル
クトレ， ヨハネス ル
ヘンリー マークラム，
ヘンリー マークラム，
マウリツィオ ペッツォーリ，
マウリツィオ ペッツォーリ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of JP2016524609A publication Critical patent/JP2016524609A/ja
Publication of JP2016524609A5 publication Critical patent/JP2016524609A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
    • C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
    • C07C35/12—Menthol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2016514430A 2013-05-24 2014-05-23 メントール及び／又はイシリンを用いるうつ病の処置又は予防 Withdrawn JP2016524609A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827256P 2013-05-24 2013-05-24
US61/827,256 2013-05-24
PCT/EP2014/060634 WO2014187943A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of depression using menthol and/or icilin

Publications (2)

Publication Number Publication Date
JP2016524609A true JP2016524609A (ja) 2016-08-18
JP2016524609A5 JP2016524609A5 (enExample) 2017-06-29

Family

ID=50841770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016514430A Withdrawn JP2016524609A (ja) 2013-05-24 2014-05-23 メントール及び／又はイシリンを用いるうつ病の処置又は予防

Country Status (8)

Country Link
US (1) US20160108005A1 (enExample)
EP (1) EP3003294A1 (enExample)
JP (1) JP2016524609A (enExample)
CN (1) CN105263481A (enExample)
AU (1) AU2014270339A1 (enExample)
BR (1) BR112015028884A2 (enExample)
CA (1) CA2908378A1 (enExample)
WO (1) WO2014187943A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116076776A (zh) * 2022-12-19 2023-05-09 惠州市新泓威科技有限公司 具有抑制单胺氧化酶活性作用的电子烟雾化液
CN116158550A (zh) * 2022-12-19 2023-05-26 惠州市新泓威科技有限公司 具有抗抑郁作用的电子烟雾化液及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2651865C (en) * 2006-05-10 2015-11-24 Janssen Pharmaceutica N.V. Cold menthol receptor-1 antagonists
AU2008275927B8 (en) * 2007-07-18 2014-08-14 Janssen Pharmaceutica N.V. Sulfonamides as TRPM8 modulators
US8217060B2 (en) * 2009-05-15 2012-07-10 Janssen Pharmaceutica, Nv Benzimidazole derivatives useful as TRP M8 receptor modulators
JP6205133B2 (ja) * 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
JP2012193176A (ja) * 2011-03-03 2012-10-11 Nippon Zoki Pharmaceut Co Ltd ミルナシプラン含有経皮吸収用医薬組成物
CN102258751A (zh) * 2011-07-21 2011-11-30 泰一和浦（北京）中医药研究院有限公司 用于治疗忧郁症、消愁解忧、善解抑郁的中药薄荷
JP5376481B1 (ja) * 2013-03-04 2013-12-25 日本臓器製薬株式会社 経皮吸収用医薬組成物

Also Published As

Publication number Publication date
AU2014270339A1 (en) 2015-10-08
CA2908378A1 (en) 2014-11-27
WO2014187943A1 (en) 2014-11-27
BR112015028884A2 (pt) 2017-07-25
EP3003294A1 (en) 2016-04-13
US20160108005A1 (en) 2016-04-21
CN105263481A (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
JP2016524608A (ja) メントール、リナロール及び／又はイシリンを用いる神経変性疾患の処置又は予防
AU2019222781B2 (en) Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using Menthol, Linalool and/or Icilin
JP2016524609A (ja) メントール及び／又はイシリンを用いるうつ病の処置又は予防
EP3169170B1 (en) Composition comprising cinnamaldehyde and zinc
US10159653B2 (en) Methods and compositions for increasing energy expenditure using cinnamaldehyde
US11241433B2 (en) Treatment or prevention of autism disorders using menthol, linalool and/or icilin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170517

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180309